Typhoid fever and Paratyphold A.B. (Cinical and laboratory diagnostics. Complications. Treatment) tell me each and everything about these disease
Reading File
Finding Sources
Finding Sources
Searching the Web
typhoid fever paratyphoid clinical features diagnosis treatment complications 2024
Reading File
Reading File
Reading File
Reading File
Reading File
Searching Images
typhoid fever rose spots rash Salmonella typhi
This clinical photograph shows an intraoperative view of an exploratory laparotomy, demonstrating a bowel perforation in the context of typhoid fever (Salmonella Typhi). The image focuses on a loop of small intestine held by a surgeon's gloved hands, revealing a discrete, longitudinal perforation with hyperemic and slightly everted edges. The surrounding serosa exhibits generalized inflammation and congestion. In the background, other segments of the intestine appear edematous and pale-pink, with visible white-yellowish peritoneal nodules and purulent exudate suggestive of concurrent miliary peritoneal tuberculosis and secondary peritonitis. Surgical instruments, suction tubing, and green sterile drapes define the surgical field. This image serves as an educational example of the severe gastrointestinal complications of typhoid fever, specifically intestinal perforation, and illustrates the challenging clinical scenario of co-infection with tuberculosis in an acute surgical setting.
A diagnostic Western blot (WB) analysis image showing the immunoreactivity of antigens derived from Salmonella typhi and Salmonella spp. The image displays six experimental lanes representing three different protein extraction methods—Whole Cell Protein (WCP), Cell Surface Protein (CSP), and sodium deoxycholate-extracted WCP (sdWCP)—for each bacterial species. A molecular weight (MW) marker lane on the far left, stained with Ponceau S, shows reference bands from 40 kDa to 70 kDa. The WB profile is categorized into three vertical regions: R1 (≥ 55 kDa), R2 (54–34 kDa), and R3 (< 34 kDa). Prominent, high-intensity immunoreactive bands are observed in both species at approximately 70 kDa and 46 kDa, with a noticeable smear in the CSP lanes. Low molecular weight bands are consistently identified at 13 kDa and 15 kDa across all preparations. This visual provides comparative data on the antigenic profiles and antibody isotype reactivity against somatic and flagellar antigens, relevant for typhoid fever serodiagnosis research.
This monochrome clinical photograph captures an intraoperative view of the abdominal cavity during a surgical procedure for bowel perforation. The image illustrates two distinct infectious pathologies concurrently affecting the intestines and peritoneum. Label 'A' identifies a typhoid intestinal perforation, appearing as an irregular, longitudinal breach in the seromuscular layer of the small bowel, typical of advanced Salmonella typhi infection. Label 'B' shows a non-perforated typhoid lesion, characterized by localized inflammation and thickening without a full-thickness defect. Surrounding these intestinal segments, multiple small, discrete, whitish nodules are indicated by label 'C', representing miliary peritoneal tuberculosis. These nodules are scattered across the serosal surfaces and mesentery, demonstrating a grain-like distribution characteristic of disseminated mycobacterial infection. The image serves as a high-level educational example of acute surgical abdomen complications resulting from co-infection of typhoid fever and miliary tuberculosis, highlighting diagnostic landmarks such as transmural perforation and widespread peritoneal seeding.
Reading File
Reading File
Loading Image
I now have rich, authoritative data from Harrison's 22E (2025), Tintinalli's Emergency Medicine, and Park's Preventive Medicine. Here is a complete, detailed answer:
Typhoid Fever & Paratyphoid A, B, C - Complete Guide
Sources: Harrison's Principles of Internal Medicine 22E (2025), Tintinalli's Emergency Medicine, Park's Textbook of Preventive and Social Medicine, CDC Guidelines
1. DEFINITION & CAUSATIVE ORGANISMS
Enteric fever is the collective term for both typhoid and paratyphoid fevers. They are clinically indistinguishable.
| Disease | Organism | Notes |
|---|---|---|
| Typhoid fever | Salmonella enterica serovar Typhi (S. Typhi) | More severe |
| Paratyphoid A | S. enterica serovar Paratyphi A | Milder, gastrointestinal-predominant |
| Paratyphoid B | S. enterica serovar Paratyphi B | Less common |
| Paratyphoid C | S. enterica serovar Paratyphi C | Rare |
- Man is the ONLY reservoir - no animal reservoir exists for any of these organisms (unlike non-typhoidal Salmonella)
- Gram-negative, facultative anaerobic, motile bacilli
- Killed by drying, pasteurization, and common disinfectants
- S. Paratyphi A thought to cause milder disease, but a large prospective study (Kathmandu, Nepal, n=669) found typhoid and paratyphoid clinically indistinguishable
2. EPIDEMIOLOGY
- Global burden: 9.2-21 million cases of typhoid and ~5 million cases of paratyphoid per year; 110,000-280,000 deaths/year
- Highest burden: Indian subcontinent (India, Pakistan, Bangladesh, Nepal), Eastern Mediterranean, sub-Saharan Africa, Southeast Asia, some Pacific regions
- Incidence can exceed 1,000 cases per 100,000 children in some urban areas
- High correlation with mixing of drinking water and human sewage
- In endemic regions: more common in poor urban neighborhoods, children, and adolescents
- Peak age: 5-19 years; incidence falls after age 20 (immunity acquired from subclinical infection)
- Males more commonly infected; carrier rate higher in females
Risk factors:
- Contaminated drinking water or ice
- Food from street vendors
- Raw fruits/vegetables grown in sewage-fertilized fields
- Ill household contacts
- Poor hand hygiene
- Prior H. pylori infection (reduced gastric acidity)
- International travel (78% of US cases are travel-associated, mainly from Indian subcontinent)
3. TRANSMISSION & PATHOGENESIS
Transmission: Fecal-oral route - feces and urine of cases or carriers contaminate water, food, fingers, and flies ("the 5 Fs")
Dose-dependent: Disease severity varies with infecting dose and host immune status
Pathogenesis steps:
- Ingestion of organism - gastric acid is a major barrier (reduced gastric acid = higher susceptibility)
- Penetration of small intestinal mucosa via M cells overlying Peyer's patches
- Uptake by macrophages - survive and replicate intracellularly (this is why cell-mediated immunity is the primary defense)
- Spread to mesenteric lymph nodes → thoracic duct → bloodstream = primary bacteremia (end of incubation)
- Seeding of reticuloendothelial system (liver, spleen, bone marrow) and gallbladder
- Secondary bacteremia - produces clinical illness
- In the third week - Peyer's patches become necrotic and ulcerate, risking perforation and hemorrhage
- Organisms can persist in gallbladder for years (chronic carrier state)
4. CLINICAL FEATURES (WEEK BY WEEK)
Incubation period: 5-21 days (mean 10-14 days for S. Typhi)
Week 1 - Onset
- Step-ladder fever rising to 38.8-40.5°C (101.8-104.9°F)
- Headache (80%), chills (35-45%), malaise
- Cough (30%), myalgia (20%), arthralgia
- Relative bradycardia (pulse slow relative to the height of fever - "Faget's sign") - present in <50% of cases
- Anorexia (55%), nausea (18-24%), vomiting (18%)
- Constipation more common than diarrhea in early stages
- Coated tongue (51-56%)
Week 2 - Full Illness
- High continuous fever, now well established
- "Rose spots" - faint, salmon-colored, blanching, maculopapular rash on the trunk and chest
- Appear in ~30% of patients at end of week 1 to beginning of week 2
- 2-4 mm, blanch on pressure, fade without scarring
- Seen best in fair-skinned individuals
- Represent Salmonella-infected macrophages in the skin
- Splenomegaly and hepatomegaly (5-6%)
- Abdominal distension, diarrhea (22-28%) or constipation (13-16%)
- Epistaxis in some patients
Week 3-4 - Complications or Recovery
- Severe: intestinal hemorrhage or perforation
- Neurological manifestations possible
- Without treatment: fever persists for up to 4 weeks
Paratyphoid A, B, C - clinically the same as typhoid but generally:
- Milder course with shorter duration
- More prominent gastrointestinal symptoms from the start
- Lower complication and fatality rates
5. LABORATORY DIAGNOSTICS
Blood Tests
| Test | Findings |
|---|---|
| CBC | Leukopenia (WBC often 3,000-5,000/mm³), mild anemia, thrombocytopenia |
| Liver enzymes | Mildly elevated ALT/AST (hepatitis pattern in some) |
| ESR | Elevated |
| CRP | Elevated |
- Leukocytosis can occur in children and with intestinal perforation (should raise suspicion for complication)
Microbiological Cultures (Gold Standard)
| Specimen | Optimal Timing | Sensitivity |
|---|---|---|
| Blood culture | Week 1-2 | 40-80% (most sensitive in 1st week) |
| Bone marrow culture | Any time | 90-95% - most sensitive overall (positive even after antibiotics started) |
| Stool culture | Week 2-3 | 30-50% |
| Urine culture | Week 2-3 | 25-30% |
| Bile (duodenal drainage) | Carrier detection | High yield in chronic carriers |
Key points:
- Blood cultures are the most practical first-line test
- Bone marrow culture is the definitive test - organism can be recovered even after antibiotic treatment has begun
- Stool cultures become positive in weeks 2-3 as organisms shed via bile into the gut
Serological Tests
Widal Test (Widal Reaction)
- Detects agglutinating antibodies against O (somatic) and H (flagellar) antigens of S. Typhi
- O antibodies - appear in week 1, rise in weeks 2-3, fall quickly after recovery - indicates active infection
- H antibodies - appear later, persist for months/years - may reflect past infection or vaccination
- Diagnostic criteria: 4-fold rise in paired sera (taken 2 weeks apart) OR single titre ≥1:160 (O) in a non-endemic area
- Limitations: Low sensitivity and specificity; false positives in other Salmonella infections, malaria, liver disease, and in vaccinated individuals; results vary by lab
- Not reliable for diagnosis in endemic areas where baseline titres may be elevated
- For paratyphoid: similar test using Paratyphi A (AO, AH), B (BO, BH) antigens
Typhidot / Typhidot-M
- IgM and IgG ELISA against a specific 50-kDa outer membrane protein of S. Typhi
- Typhidot-M (detects IgM only) is more specific - eliminates IgG that persists from previous infection
- Results available in 3-4 hours
- Better than Widal in endemic areas
Tubex Test
- Detects IgM antibodies to O9 antigen of S. Typhi
- Rapid test, good specificity
- Does not cross-react with vaccination
Blood culture PCR
- High sensitivity, identifies organisms even after antibiotic initiation
- Not universally available
Key Diagnostic Approach Summary
- Culture blood in week 1 (best yield)
- Culture stool + urine from week 2
- Bone marrow culture if blood culture negative and high clinical suspicion
- Widal test - supportive evidence only (not definitive in endemic areas)
- Rapid tests (Typhidot, Tubex) for resource-limited settings
6. DIFFERENTIAL DIAGNOSIS
- Malaria - most important; always exclude first in travelers
- Brucellosis
- Leptospirosis
- Typhus / Rickettsiosis
- Dengue fever
- Sepsis from other causes
- Viral hepatitis
- Tuberculosis (in chronic fever)
Clinical clue: A febrile traveler from an endemic area not responding to antimalarial medication should be suspected to have enteric fever
7. COMPLICATIONS (10-15% of hospitalized patients)
Complications typically occur after 2-3 weeks of illness (when Peyer's patch ulceration is maximal):
Gastrointestinal
| Complication | Details |
|---|---|
| Intestinal hemorrhage | Erosion of Peyer's patches into blood vessels; presents with melena or bright rectal bleeding in week 3; occurs in 1-5% |
| Intestinal perforation | Most feared; ileal perforation near ileocecal valve; presents as acute abdomen; 1-3% incidence; mortality 10-32% even with surgery |
| Hepatitis | Mild jaundice and elevated transaminases in up to 40% |
| Cholecystitis | Acute or chronic; gallbladder is the reservoir for carriers |
Cardiovascular
- Myocarditis - ECG changes, arrhythmias
- Mycotic aneurysm (rare)
Hematological
- DIC (Disseminated Intravascular Coagulopathy)
- Severe anemia (from GI blood loss + hemolysis)
- Thrombocytopenia
Neurological ("Typhoid Encephalopathy")
- Altered consciousness, confusion, delirium
- Meningismus, seizures
- Psychosis
- Ataxia, cranial nerve palsies
- Deafness (sensorineural - a specific sequela)
- Occurs in 1-10% of severe cases
Respiratory
- Pneumonia (bronchopneumonia)
- Pleural effusion
Renal
- Glomerulonephritis, renal failure (rare)
Other
- Septic arthritis
- Osteomyelitis (especially in sickle cell disease)
- Pancreatitis
8. RELAPSE
- Occurs in ~10% of inadequately treated patients (and some adequately treated)
- Typically 1-3 weeks after clinical recovery (CDC) / "2-3 weeks after recovery" (MSF 2024)
- Relapse illness is usually milder than the primary attack
- Usually NOT due to antibiotic resistance
- Re-treatment with the same antibiotic is usually effective
- Second relapse possible (rare)
9. CARRIER STATE
- Chronic carrier: Excretion of S. Typhi in stool or urine for >1 year after infection
- Affects 1-4% of typhoid fever cases (Park: 2-5%)
- Organisms persist in the gallbladder and biliary tract
- More common in women, elderly, and those with pre-existing gallbladder disease
- The famous historical case: "Typhoid Mary" (Mary Mallon) - caused >1,300 cases over her lifetime
- Faecal carriers more frequent than urinary carriers
- Chronic urinary carrier state often associated with urinary tract abnormalities
- Vi antibody detected in ~80% of chronic carriers (useful screening test)
10. TREATMENT
General Principles
- Antibiotics shorten clinical course, reduce complication risk, and lower mortality
- Treatment decisions complicated by high rates of antimicrobial resistance
- Susceptibility testing should guide treatment whenever possible
Antibiotic Resistance Profile
| Drug Category | Resistance Situation |
|---|---|
| Chloramphenicol, Ampicillin, TMP-SMX | MDR strains widely prevalent since 1980s; unreliable |
| Fluoroquinolones | Decreased susceptibility to ciprofloxacin (DSC) widespread on Indian subcontinent (66% of US travel-acquired cases from India); full resistance emerging |
| Ceftriaxone / 3rd gen cephalosporins | Generally effective; resistance emerging |
| Azithromycin | Effective for uncomplicated typhoid; resistance emerging in some areas |
| XDR (Extensively Drug Resistant) S. Typhi | Pakistan outbreak 2016-2019; resistant to all 1st-line + fluoroquinolones + 3rd-gen cephalosporins; only azithromycin and carbapenems active |
Antibiotic Regimens
Uncomplicated typhoid fever (oral, outpatient):
| Drug | Dose | Duration |
|---|---|---|
| Azithromycin | 500 mg OD (or 1g on day 1 then 500 mg) | 5-7 days |
| Cefixime | 15-20 mg/kg/day in 2 divided doses | 7-14 days |
| Ciprofloxacin (if susceptible) | 500 mg BD | 5-7 days |
Severe/complicated typhoid fever (hospitalized, IV):
| Drug | Dose | Duration |
|---|---|---|
| Ceftriaxone | 2 g IV OD (adults); 60 mg/kg/day in children | 10-14 days |
| Azithromycin IV (if available) | 500 mg OD | 7-10 days |
| Meropenem | For XDR typhoid; 1 g IV TDS | 14 days |
Adjuvant treatment for severe toxicity/encephalopathy:
- Dexamethasone 3 mg/kg IV loading dose, then 1 mg/kg every 6 hours for 48 hours (for typhoid shock or encephalopathy)
- Reduces mortality in severe disease with neurological involvement
Supportive Treatment
- IV rehydration
- Antipyretics (paracetamol; avoid NSAIDs due to GI bleeding risk)
- Blood transfusion if significant GI blood loss
- Nutritional support
- Close monitoring for complications (abdominal exam, stool examination)
Treatment of Complications
| Complication | Management |
|---|---|
| Intestinal hemorrhage | IV fluids, blood transfusion, conservative management initially; surgery if massive bleeding |
| Intestinal perforation | Emergency surgery (primary repair or resection), IV antibiotics covering gram-negatives and anaerobes |
| Typhoid encephalopathy | Dexamethasone + antibiotics |
| DIC | Fresh frozen plasma, platelets, heparin in some cases |
Treatment of Chronic Carriers
- Ampicillin or Amoxicillin 4-6 g/day + Probenecid 2 g/day for 6 weeks (concentrated in bile; eradicates carrier state in ~70%)
- Ciprofloxacin 750 mg BD for 4 weeks (preferred if susceptible)
- Cholecystectomy with concurrent antibiotic therapy - reserved for carriers with gallstones when medical treatment fails
- Chloramphenicol is ineffective at clearing the carrier state
11. PARATYPHOID A, B, C - SPECIFIC NOTES
| Feature | Typhoid | Paratyphoid A | Paratyphoid B | Paratyphoid C |
|---|---|---|---|---|
| Organism | S. Typhi | S. Paratyphi A | S. Paratyphi B | S. Paratyphi C (rare) |
| Severity | More severe | Milder (but not always) | Milder | Variable |
| Predominant symptoms | Systemic > GI | GI-predominant | GI-predominant | Variable |
| Carrier rate | 1-4% | Lower | Lower | - |
| CFR | ~1% (treated) | ~0.5% (roughly half) | ~0.5% | - |
| Rose spots | Yes (~30%) | Can occur | Can occur | - |
| Treatment | Same as above | Same as above | Same as above | Same |
| Widal | O/H agglutinins | AO, AH agglutinins | BO, BH agglutinins | CO, CH |
- Paratyphoid fever accounts for ~5 million cases/year globally
- S. Paratyphi A is the most common paratyphoid
- Paratyphoid is slightly more common in older adults (median age 29 vs 23 for typhoid in US data)
- Complications occur less frequently but are otherwise the same in type
- The two diseases cannot be distinguished on clinical grounds - only culture separates them
12. PROGNOSIS & MORTALITY
| Scenario | Mortality |
|---|---|
| Pre-antibiotic era typhoid | >10-30% |
| Treated typhoid (modern) | <1% |
| With intestinal perforation | 10-32% |
| Paratyphoid (treated) | ~0.5% - lower than typhoid |
| MDR/XDR typhoid untreated | Higher |
- With early diagnosis and appropriate treatment, mortality is ~1%
- Without treatment: disease lasts ~4 weeks; historical mortality 10-30%
13. PREVENTION & CONTROL
Vaccination
| Vaccine | Type | Route | Efficacy | Duration |
|---|---|---|---|---|
| Ty21a (Vivotif) | Live attenuated oral | Oral (4 capsules) | 50-80% | 3-7 years |
| Vi polysaccharide (ViPS) | Injectable subunit | IM | 55-72% | 2-3 years |
| Typhoid conjugate vaccine (TCV, Typbar-TCV) | Vi conjugated to tetanus toxoid | IM single dose | >80% | Longer; protective in <2 yrs |
- No vaccine covers paratyphoid - vaccines only protect against S. Typhi
- WHO recommends TCV for routine use in children >6 months in endemic countries
- Vaccines are not 100% effective - food and water precautions remain essential
Sanitation & Control
- Safe water supply and sewage treatment are the most important measures
- The "weakest link" in transmission is sanitation (most amenable to control)
- Food handling hygiene, hand washing
- Identification and treatment of chronic carriers
- Isolation of cases until 3 bacteriologically negative stool and urine samples obtained
- Disinfection: 5% cresol for 2 hours (stools and urine); 2% chlorine for soiled linen
Summary Table - At a Glance
| Feature | Detail |
|---|---|
| Causative agent | S. Typhi (typhoid); S. Paratyphi A, B, C (paratyphoid) |
| Only reservoir | Humans (cases + carriers) |
| Incubation | 5-21 days (mean 10-14 days) |
| Classic fever | Step-ladder, continuous, 38.8-40.5°C |
| Pathognomonic sign | Rose spots on trunk (30% of cases) |
| Relative bradycardia | <50% of cases |
| Gold standard diagnosis | Blood culture (week 1); bone marrow culture (any time, most sensitive) |
| Widal test | Supportive only; unreliable in endemic areas |
| Complications | Perforation, hemorrhage, encephalopathy, DIC, myocarditis |
| Complication timing | Week 3+ |
| Drug of choice | Azithromycin (uncomplicated, oral); Ceftriaxone (severe, IV) |
| Dexamethasone | Add for shock/encephalopathy |
| Chronic carrier Rx | Ciprofloxacin 750 mg BD x 4 weeks |
| Mortality (treated) | <1% (typhoid); ~0.5% (paratyphoid) |
Sources: Harrison's Principles of Internal Medicine 22E (2025), Tintinalli's Emergency Medicine (comprehensive study), Park's Textbook of Preventive and Social Medicine, CDC Clinical Guidance 2024, MSF Medical Guidelines March 2024
This is a shared conversation. Sign in to Orris to start your own chat.